Influence of Organic Anion Transporting Polypeptide1B1(OATP1B1) Genotype on Rosuvastatin PK, PD and Lipid Profiles
NCT ID: NCT01218347
Last Updated: 2011-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
34 participants
INTERVENTIONAL
2010-10-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Influence of OATP1B1 and BRCP Genotype on Rosuvastatin PK, PD and Lipidomics in Hyperlipidemic Patients
NCT01466608
Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients
NCT00631189
Tolerability and Efficacy of Rosuvastatin - Fenofibrate Combine Therapy in Korean Patients With Combined Hyperlipidemia
NCT01414803
A Clinical Study to Evaluate PK, PD, and PG of Rosuvastatin in the Elderly
NCT03715101
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants
NCT07088913
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Rosuvastatin are administered once a day for 21 days. Before and after rosuvastatin administration, PK, PD and lipid profiles are investigated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rosuvastatin
rosuvastatin treatment
Rosuvastatin
20 mg once daily for 21 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rosuvastatin
20 mg once daily for 21 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Weight: Over 55 kg, within ±20% of ideal body weight
* Must be reliable and willing to make themselves available during the study period
* Must be willing to give blood sample for genotyping
Exclusion Criteria
* History of a significant surgical resection of gastrointestinal tract except appendectomy
* History or evidence of drug abuse
* Use any medication during the last 14 days period before first dosing
* Hypersensitivity to HMG-CoA reductase inhibitor
* Judged to be inappropriate for the study by the investigator
20 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seoul National University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kyung-Sang Yu, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University College of Medicine and Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trials Center, Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SNUCPT10_Rosuvastatin_OATP1B1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.